Abstract:Abnormal accumulation of misfolded and hyperphosphorylated tau protein in brain is the defining feature of several neurodegenerative diseases called tauopathies, including Alzheimer's disease (AD). In AD, this pathological change is reflected by highly specific cerebrospinal fluid (CSF) tau biomarkers, including both phosphorylated and non-phosphorylated variants. Interestingly, despite tau pathology being at the core of all tauopathies, CSF tau biomarkers remain unchanged in certain tauopathies, e.g., progressive supranuclear palsy (PSP), Pick's disease (PiD), and corticobasal neurodegeneration (CBD). To better understand commonalities and differences between tauopathies, we report a multiplex assay combining immunoprecipitation and high-resolution mass spectrometry capable of detecting and quantifying peptides from different tau protein isoforms as well as non-phosphorylated and phosphorylated peptides, including those carrying multiple phosphorylations. We investigated the tau proteoforms in soluble and insoluble fractions of brain tissue from subjects with autopsy-confirmed tauopathies, including sporadic AD (n = 10), PSP (n = 11), PiD (n = 10), and CBD (n = 10), and controls (n = 10). Our results demonstrate that non-phosphorylated tau profiles differ across tauopathies, generally showing high abundance of microtubule-binding region (MTBR)-containing peptides in insoluble protein fractions compared with controls; the AD group showed 12-72 times higher levels of MTBR-containing aggregates. Quantification of tau isoforms showed the 3R being more abundant in PiD and the 4R isoform being more abundant in CBD and PSP in the insoluble fraction. Twenty-three different phosphorylated peptides were quantified. Most phosphorylated peptides were measurable in all investigated tauopathies. All phosphorylated peptides were significantly increased in AD insoluble fraction. However, doubly and triply phosphorylated peptides were significantly increased in AD even in the soluble fraction. Results were replicated using a validation cohort comprising AD (n = 10), CBD (n = 10), and controls (n = 10). Our study demonstrates that abnormal levels of phosphorylation and aggregation do indeed occur in non-AD tauopathies, however, both appear pronouncedly increased in AD, becoming a distinctive characteristic of AD pathology.

Threonine175, a novel pathological phosphorylation site on tau protein linked to multiple tauopathies

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease

Tau protein profiling in tauopathies: a human brain study

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease

Phosphorylation at serine 214 correlates with tau seeding activity in an age-dependent manner in two mouse models for tauopathies and is required for tau transsynaptic propagation.

Uncovering elevated tau TPP motif phosphorylation in the brain of Alzheimer's disease patients

Tau phosphosignatures discriminate Alzheimer Disease from other tauopathies

Phosphorylation of Tau at Threonine 231 in Patients With Multiple System Atrophy and in a Mouse Model

Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia

Mass spectrometry identifies tau C-terminal phosphorylation cluster during neuronal hyperexcitation

A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer’s disease brain

Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer's Disease

A Unique Tau Conformation Generated by an Acetylation-Mimic Substitution Modulates P301S-dependent Tau Pathology and Hyperphosphorylation.

Single-molecule imaging of Tau reveals how phosphorylation affects its movement and confinement in living cells

O4‐12‐03: Brain Phosphoproteome Network Analysis Discriminates Alzheimer's Disease from Other Tauopathies

Functional classification of tauopathy strains reveals the role of protofilament core residues.

Hyperacetylation mimetics within the tau filament core inhibits prion-like propagation of misfolded tau

Argyrophilic Grain Disease Differs from Other Tauopathies by Lacking Tau Acetylation

Molecular Polymorphism of tau aggregates in Pick's disease